Objective: The medicines off-label using are characterized by the prescription of a drug in a different way from that reported by the leaflet and / or indication not registered by the regulatory agency in a specific country. Taking note about the growth of such prescriptions, this article aims to evaluate the drug Topiramate offlabel using. Method: A systematic review of studies reported in the literature was performed, using the Pubmed database as a reference for researching. From those selected articles (n=8) the off label Topiramate prescription occurred for the treatment of alcohol dependence and its abstinence, simultaneous dependence on cocaine and / or opioids, obesity and Obsessive Compulsive Disorder (OCD). Results: Significant results were observed in the off-label Topiramate using in all of the aforementioned studies (100%), as well as reported by the authors the presence of ADRs in the subjects being treated in 75% of the developed trials (paresthesia, dysgeusia, insomnia, difficulty in concentration and memory, headache, nausea, among others). Conclusion: Such evidence requires special attention in the clinical pharmacy context, and points to the need for further studies and results that justify the prescription of those drugs, such as Topiramate, and demonstrate efficacy and safety so that their use in clinical practice is regulated.